News

The ERS Pulmonary Hypertension Research Award will grant €40,000 to a pair of carefully selected scientists currently pursuing active research projects in the field of pulmonary hypertension, with regard to its pathophysiology, basic science, epidemiology, clinical practice, prevention, treatment, diagnosis or rehabilitation. The awards are reserved exclusively for candidates younger than 45 years old at the time…

Biopharmaceutical company MediciNova recently announced that MN-001 (tipelukast) has been approved for clinical trials by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe idiopathic pulmonary fibrosis (IPF). MN-001 is an orally-available small…

A new study out of Toronto, Canada has evaluated whether rheumatoid arthritis-associated pulmonary arterial hypertension (RA-PAH) is a more severe disease compared to idiopathic pulmonary arterial hypertension (IPAH). Published on January 13, 2015, the study is titled “Survival in rheumatoid arthritis-associated pulmonary arterial hypertension compared…

Earlier in the week, Pulmonary Hypertension News reported on how the drug Bosentan improved Pulmonary Hypertension Secondary to IPF in an individual case study. In a related story, medical researchers from the Academic Medical Center in Amsterdam, Netherlands, are currently recruiting adult patients (>18) with congenital heart…

Cynata Therapeutics Ltd., an Australian regenerative medicine company developing a therapeutic stem cell platform technology called Cymerus™, has announced the launch of a study to evaluate the platform’s efficacy in treating an animal model of pulmonary fibrosis (PF) — a condition that frequently results in pulmonary…

A study published in the journal Respiratory Medicine Case Reports revealed a case where a patient with idiopathic pulmonary fibrosis (IPF) was successfully treated for severe pulmonary hypertension (PH) with bosentan. The study is entitled “Bosentan for…

Despite improved understanding of the etiology of pulmonary arterial hypertension (PAH), the condition remains a severe and progressive disease, ultimately leading to right-sided cardiac failure. It continues to register significant morbidity and early mortality, with estimates showing that 1,000 Americans are diagnosed with PAH per year. Research and clinical advancements over…

A group of pulmonary medical specialists from the University of South Paris School of Medicine (USPSM) in France have conducted a robust review study that examines the increasing number of potential novel therapeutic drug targets for patients with pulmonary arterial hypertension (PAH).  The study team, led by…

A recent systematic review conducted by a research team from the University of Toronto in Canada sought to present the current state of agreement regarding the appropriate physical examination necessary for diagnosis of pulmonary hypertension (PH). The review, entitled “Utility of the Physical Examination in Detecting Pulmonary…

Calorie restriction has been recently popular as a way to stave off the aging process. Could this technique be effective for improving a disease, such as pulmonary arterial hypertension (PAH)? Researchers at Central Hospital in Xi’an China seem to think so. A recent report published in the J…

SteadyMed Ltd., an Israel-based pharmaceutical company developing and commercializing therapeutic candidates to address the limitations of top market products in treating orphan diseases, recently announced that it raised $12.2 million in equity financing to fund its PAH drug development efforts. The financing round was led by subsidiaries of Deerfield Management Company…

Tiny biomarkers for pulmonary hypertension in patients with systemic sclerosis (SSc) may be floating around affected individuals’ bloodstreams. Matthew R. Lammi, MD, of Louisiana State University Health Sciences Center in New Orleans is heading a clinical trial to evaluate the presence of endothelial microparticles (EMPs) in SSc patients with…